2-N-[2-(3-fluorophenyl)ethyl]-9-propyl-8-pyrazol-1-ylpurine-2,6-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-N-[2-(3-fluorophenyl)ethyl]-9-propyl-8-pyrazol-1-ylpurine-2,6-diamine
• 化学式: C₁₉H₂₁FN₈
• 分子量: 380.4
• InChiKey: YTUXNMSJSKTQRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  99.5
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• A3 ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Zablocki Jeff

  公开号：US20090099212A1

  公开（公告）日：2009-04-16

  Disclosed are novel methods of antagonizing the A 3 adenosine receptor in a mammal, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the formula: wherein R is hydrogen or acyl; R 1 is hydrogen, halo, optionally substituted C 1-4 alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl; R 2 is optionally substituted C 1-4 alkyl; Y is C 1-4 alkylene; and Z is phenyl, optionally substituted with halo, optionally substituted C 1-4 alkyl, or C 1-4 alkoxy. The A 3 adenosine receptors may be antagonized in order to treat a disease state is chosen from renal failure, nephritis, hypertension, oedemas, Alzheimers disease, stress, depression, cardiac arrhythmia, restoration of cardiac function, asthma, respiratory disorders, ischemia-induced injury of the brain, heart and kidney, and diarrhea. Preferred compounds selectively antagonize A 3 adenosine receptors over A 1 adenosine receptors, A 2A adenosine receptors and A 2B adenosine receptors.

  本发明涉及一种在哺乳动物中拮抗A3腺苷受体的新方法，包括向需要治疗的哺乳动物中给予化合物的治疗有效剂量，该化合物的结构式为：其中R为氢或酰基；R1为氢、卤素、可选取代的C1-4烷基、可选取代的烯基、可选取代的芳基或可选取代的杂环基；R2为可选取代的C1-4烷基；Y为C1-4烷基；Z为苯基，可选取代卤素、可选取代的C1-4烷基或C1-4烷氧基。可以拮抗A3腺苷受体以治疗肾功能衰竭、肾炎、高血压、水肿、阿尔茨海默病、压力、抑郁症、心律失常、恢复心脏功能、哮喘、呼吸系统疾病、缺血性脑、心脏和肾脏损伤以及腹泻等疾病状态。优选的化合物选择性地拮抗A3腺苷受体而不是A1腺苷受体、A2A腺苷受体和A2B腺苷受体。
• PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS
  申请人：CV THERAPEUTICS, INC.

  公开号：EP1401837B1

  公开（公告）日：2005-10-19
• A1 ADENOSINE RECEPTOR ANTAGONISTS
  申请人：CV THERAPEUTICS, INC.

  公开号：EP1646390B1

  公开（公告）日：2008-10-08
• US7238700B2
  申请人：——

  公开号：US7238700B2

  公开（公告）日：2007-07-03
• [EN] A3 ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR A3 DE L'ADÉNOSINE
  申请人：CV THERAPEUTICS INC

  公开号：WO2009052310A1

  公开（公告）日：2009-04-23

  Disclosed are novel methods of antagonizing the A3 adenosine receptor in a mammal, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the formula: wherein R is hydrogen or acyl; R1 is hydrogen, halo, optionally substituted C1-4 alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl; R2 is optionally substituted C1-4 alkyl; Y is C1-4 alkylene; and Z is phenyl, optionally substituted with halo, optionally substituted C1-4 alkyl, or C1-4 alkoxy. The A3 adenosine receptors may be antagonized in order to treat a disease state is chosen from renal failure, nephritis, hypertension, oedemas, Alzheimers disease, stress, depression, cardiac arrhythmia, restoration of cardiac function, asthma, respiratory disorders, ischemia- induced injury of the brain, heart and kidney, and diarrhea. Preferred compounds selectively antagonize A3 adenosine receptors over A1 adenosine receptors, A2A adenosine receptors and A2B adenosine receptors.